Transmyocardial and Endovascular Laser Revascularization — CPB 0163 | AETNA Coverage Update

TL;DR: Aetna modified CPB 0163 covering transmyocardial laser revascularization (TMLR), effective September 26, 2025. Here's what changes for billing teams.

Aetna, a CVS Health company, updated its transmyocardial laser revascularization coverage policy under CPB 0163 in Aetna's policy system. The revision confirms medical necessity coverage for open chest and thoracoscopic TMLR approaches — billed under CPT 33140 and CPT 33141 — when specific patient selection criteria are met. If your practice or facility bills these codes for refractory angina patients, this policy update affects your documentation requirements and your exposure to claim denial.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna
Policy	Transmyocardial and Endovascular Laser Revascularization
Policy Code	CPB 0163
Change Type	Modified
Effective Date	September 26, 2025
Impact Level	Medium
Specialties Affected	Cardiothoracic surgery, interventional cardiology, cardiac surgery facilities
Key Action	Audit documentation for CPT 33140 and 33141 claims to confirm all patient selection criteria are met before the effective date of September 26, 2025

---

Aetna Transmyocardial Laser Revascularization Coverage Criteria and Medical Necessity Requirements 2025

The Aetna TMLR coverage policy under CPB 0163 covers two surgical approaches: open chest (thoracotomy) and thoracoscopic. Both map to CPT 33140 and CPT 33141. Coverage is not automatic — Aetna requires the patient to meet specific selection criteria before these codes qualify for reimbursement.

The core medical necessity threshold is medically refractory, severe intractable angina. That phrase carries real weight. "Refractory" means the patient has failed conventional medical management. "Severe" and "intractable" mean the angina significantly limits the patient's function despite that treatment. You need documentation in the chart that supports all three of those descriptors — not just a diagnosis code.

Aetna's policy references an Appendix for the full selection criteria. That Appendix is the gatekeeper for CPT 33140 and 33141 reimbursement. If your clinical team isn't building operative and pre-procedure notes against those specific criteria, your claims are vulnerable.

This is where prior authorization becomes critical. For a procedure this specialized — with this narrow an indication — you should confirm Aetna's prior auth requirements for the specific plan product before scheduling. Commercial Aetna plans and self-funded plans may handle prior authorization differently. Call the payer or check the portal before the date of service.

---

Aetna TMLR Exclusions and Non-Covered Indications

This is where the policy gets complicated — and where billing teams need to pay close attention.

CPB 0163 includes three CPT codes that appear in a separate group labeled "Adipose derived stromal cells — No specific code." Those codes are CPT 38206 (hematopoietic progenitor cell harvesting, autologous), CPT 38232 (bone marrow harvesting, autologous), and CPT 38241 (hematopoietic progenitor cell autologous transplantation). These codes do not have a designated billing code for the adipose-derived stromal cell application referenced in this policy context.

The practical implication: if your facility is billing any cell-based or regenerative approaches alongside or instead of traditional TMLR, those services carry a different coverage status. The group label signals that the payer has not established covered billing codes for these services in this context. Claims submitted under those codes for this indication face a high risk of claim denial.

Endovascular laser revascularization — referenced in the policy title — is not listed among the covered CPT codes. The only covered surgical codes are CPT 33140 and 33141, both of which are thoracotomy approaches. If your facility performs endovascular approaches, verify coverage status separately before billing.

If you're not sure how the cell-based codes or endovascular approaches apply to your patient mix, talk to your compliance officer before the September 26, 2025 effective date.

---

Coverage Indications at a Glance

---

Aetna Transmyocardial Laser Revascularization Billing Guidelines and Action Items 2025

These are the steps your billing team and clinical documentation staff need to take before September 26, 2025.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Transmyocardial Laser Revascularization Under CPB 0163

Covered CPT Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
33140	CPT	Transmyocardial laser revascularization, by thoracotomy
33141	CPT	Transmyocardial laser revascularization, by thoracotomy

Not Covered / No Designated Billing Code

These codes appear in CPB 0163 under the group label "Adipose derived stromal cells — No specific code," meaning Aetna has not assigned a covered billing code for this service under this policy.

Code	Type	Description	Reason Copy
38206	CPT	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous	No specific code designated for adipose-derived stromal cell indication
38232	CPT	Bone marrow harvesting for transplantation; autologous	No specific code designated for adipose-derived stromal cell indication
38241	CPT	Hematopoietic progenitor cell (HPC); autologous transplantation	No specific code designated for adipose-derived stromal cell indication

Key ICD-10-CM Diagnosis Codes

---

A Note on the Code Set — and What's Confusing Here

The presence of CPT 38206, 38232, and 38241 in a TMLR policy deserves a plain-language explanation. These are stem cell and bone marrow harvesting codes. They don't belong in a traditional TMLR billing context — and that's the point.

Aetna's CPB 0163 covers broader cardiac regenerative therapy territory, including experimental cell-based approaches that some providers have explored as alternatives to TMLR. The policy groups these codes separately — and specifically labels them as having no designated billing code. This is Aetna saying: we know these services exist, and we haven't covered them here.

The real issue is that a billing team unfamiliar with this policy structure might see those codes in a reference document and assume they're covered. They're not. The group label is the tell. If you're building a charge capture template off the CPB 0163 code list, separate these three codes clearly from CPT 33140 and 33141. They are not covered under the same logic.

This is similar to how Aetna handles other regenerative medicine policies — the payer lists the codes it's aware of, separates covered from non-covered or unassigned, and lets the group label do the work. If you're used to reading these policies, the structure is familiar. If you're not, it reads like everything's on the same list when it isn't.

---